Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries

Probiotics and Antimicrobial Proteins 06/2011; 3(2):68-96. DOI: 10.1007/s12602-011-9076-5


Dental caries is a multifactorial disease that is a growing and costly global health concern. The onset of disease is a consequence
of an ecological imbalance within the dental plaque biofilm that favors specific acidogenic and aciduric caries pathogens,
namely Streptococcus mutans and Streptococcus sobrinus. It is now recognized by the scientific and medical community that it is neither possible nor desirable to totally eliminate
dental plaque. Conversely, the chemical biocides most commonly used for caries prevention and treatment indiscriminately attack
all plaque microorganisms. These treatments also suffer from other drawbacks such as bad taste, irritability, and staining.
Furthermore, the public demand for safe and natural personal hygiene products continues to rise. Therefore, there are opportunities
that exist to develop new strategies for the treatment of this disease. As an alternative to conventional antibiotics, antibacterial
peptides have been explored greatly over the last three decades for many different therapeutic uses. There are currently tens
of hundreds of antibacterial peptides characterized across the evolutionary spectrum, and among these, many demonstrate physical
and/or biological properties that may be suitable for a more targeted approach to the selective control or elimination of
putative caries pathogens. Additionally, many peptides, such as nisin, are odorless, colorless, and tasteless and do not cause
irritation or staining. This review focuses on antibacterial peptides for their potential role in the treatment and prevention
of dental caries and suggests candidates that need to be explored further. Practical considerations for the development of
antibacterial peptides as oral treatments are also discussed.


Download full-text


Available from: Michael L Chikindas, Oct 07, 2015
63 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: AMPs produced by bacteria are generally known as bacteriocins and are produced by either of two biosynthetic routes. They may be gene encoded or manufactured by ribosome-independent pathways. Non-ribosomal prokaryotic AMPs are generally secondary metabolites from fermentations that are assembled by large multifunctional enzyme complexes and belong to a large class of compounds that includes established antibiotics such as vancomycin and daptomycin. Gene-encoded AMPs from prokaryotes include microcins from gram-negative bacteria, lantibiotics, and non-modified bacteriocins from gram-positive bacteria. In general, these peptides show relatively narrow ranges of activity against organisms that are closely related to the host and utilize a diverse array of antimicrobial mechanisms involving specific receptors, membrane components, and intracellular targets. In this chapter, we review current knowledge of prokaryotic AMPs and the potential of these molecules for development as antimicrobial agents in areas such as food preservation and healthcare.
    Novel Antimicrobial Agents and Strategies, 11/2014: pages 71-90; , ISBN: 9783527336388
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Nisin is a lantibiotic widely used for the preservation of food and beverages. Recently, investigators have reported that nisin may have clinical applications for treating bacterial infections. The aim of this study was to investigate the effects of ultra pure food grade Nisin ZP (> 95% purity) on taxonomically diverse bacteria common to the human oral cavity and saliva derived multi-species oral biofilms, and to discern the toxicity of nisin against human cells relevant to the oral cavity. Methods: The MICs and MBCs of taxonomically distinct oral bacteria were determined using agar and broth dilution methods. To assess the effects of nisin on biofilms, two model systems were utilized: a static and a controlled flow microfluidic system. Biofilms were inoculated with pooled human saliva and fed filter-sterilized saliva for 20-22 h at 37°C. Nisin effects on cellular apoptosis and proliferation were evaluated using acridine orange/ethidium bromide fluorescent nuclear staining and lactate dehydrogenase activity assays. Results: Nisin inhibited planktonic growth of oral bacteria at low concentrations (2.5 – 50 μg/ml). Nisin also retarded development of multi-species biofilms at concentrations ≥ 1 μg/ml. Specifically, under biofilm model conditions, nisin interfered with biofilm development and reduced biofilm biomass and thickness in a dose-dependent manner. The treatment of pre-formed biofilms with nisin resulted in dose- and time-dependent disruption of the biofilm architecture along with decreased bacterial viability. Human cells relevant to the oral cavity were unaffected by the treatment of nisin at anti-biofilm concentrations and showed no signs of apoptotic changes unless treated with much higher concentrations (> 200 μg/ml). Conclusions: This work highlights the potential therapeutic value of high purity food grade nisin to inhibit the growth of oral bacteria and the development of biofilms relevant to oral diseases.
    Frontiers in Microbiology 06/2015; DOI:10.3389/fmicb.2015.00617 · 3.99 Impact Factor